Defence Therapeutics Appoints Dr. Amie Phinney as President and Chief Executive Officer
Montreal, Quebec--(Newsfile Corp. - August 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the appointment of Dr. Amie Phinney, PhD, MBA, as the President and Chief Executive Officer, effective August 1, 2026. As part of the leadership transitio
Biotechnologies, Pharmaceutique, Santé
2026-08-04 3:15 AM EDT | Defence Therapeutics Inc.
Verisante Technology, Inc. Announces Resignation of Director
Vancouver, British Columbia--(Newsfile Corp. - August 3, 2026) - Verisante Technology, Inc. (TSXV: VER.H) ("Verisante" or the "Company") announces that Dr. Jake Thiessen, PhD has resigned as a director of the Company effective August 3, 2026. "On behalf of the Board of Directors, I want to sincerely thank Dr. Thiessen for his dedication and contributions to Verisante," said Thomas Braun, Chief Executive Officer. The Company confirms that there are no matters referred to in
2026-08-03 11:51 PM EDT | Verisante Technology Inc.
WELL Health Subsidiary WELLSTAR Closes C$50 Million Financing Transaction Ahead of Planned TSXV Listing
Vancouver, British Columbia--(Newsfile Corp. - July 31, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ("WELL"), a digital health company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that its subsidiary, WELLSTAR Technologies Corp. ("WELLSTAR"), has closed a financing transaction for aggregate gross proceeds of C$50 million (the "Financing
Technologies, Logiciels, Soins de santé et hôpitaux, Santé
2026-07-31 8:17 AM EDT | WELL Health Technologies Corp.
Jack Nathan Medical Corp. Announces Board Changes and Corporate Update
Toronto, Ontario--(Newsfile Corp. - July 31, 2026) - Jack Nathan Medical Corp. (TSXV: JNH) (OTC Pink: JNHMF) ("Jack Nathan" or the "Company") announces that Blake Lyon, Chairman of the Board of Directors, and Anthony DeCristofaro, Director, have resigned from the Board of Directors of the Company (the "Board"), effective July 31, 2026. Mr. Lyon and Mr. DeCristofaro have each served the Company for many years and have contributed significant time, leadership and experience throughout the
Soins de santé et hôpitaux, Commerce de détail, Santé
2026-07-31 6:00 AM EDT | Jack Nathan Medical Corp.
Edison Issues Report on Kooth (KOO)
London, United Kingdom--(Newsfile Corp. - July 31, 2026) - Edison issues report on Kooth (AIM: KOO) Kooth provides clinically accredited digital mental health support, focused on children and young adults. H126 trading was in line with expectations. Adjusted EBITDA is expected to rise to £5.0-5.4m (H125: £1.6m), implying a c 17% margin (H125: 5%) as strong California user engagement compares with a prior year that included accelerated investment. Revenue is expected to be
Services bancaires / financiers, Matériel informatique, Logiciels, Santé
2026-07-31 5:18 AM EDT | Edison Group
Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026
Calgary, Alberta--(Newsfile Corp. - July 30, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the second tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026. The Company raised aggregate gross proceeds of CDN$322,250 under the second tranche through the issuance of 6,445,000 units ("Units") at a price of CDN$0.05
Biotechnologies, Pharmaceutique, Santé
2026-07-30 5:57 PM EDT | Hemostemix Inc.
Medexus Schedules First Fiscal Quarter 2027 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - July 30, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Tuesday, August 11, 2026 to discuss Medexus's results for its first fiscal quarter ended June 30, 2026. Medexus expects to file its financial statements and MD&A after markets close on August 10, 2026. To participate in the call, please dial the following numbers:
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-30 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Edison Issues Report on Trade Estates REIC (TRESTATES)
London, United Kingdom--(Newsfile Corp. - July 30, 2026) - Edison issues report on Trade Estates REIC (ATSE: TRESTATES). Trade Estates REIC (TRESTATES) offers focused exposure to modern retail parks and new-generation logistics assets in Greece, Cyprus and Bulgaria. Demand for both sectors is driven by structural growth trends in retail spending, and both sectors are undersupplied. In Greece, Trade Estates is dominant in modern retail parks, where active management and deep sector exper
Services bancaires / financiers, Matériel informatique, Logiciels, Santé
2026-07-30 11:21 AM EDT | Edison Group
Edison Issues Report on Fourlis Holdings (FOYRK)
London, United Kingdom--(Newsfile Corp. - July 30, 2026) - Edison issues report on Fourlis Holdings (ATSE: FOYRK). Fourlis Holdings is a leading Southeast European retailer operating exclusive long-term franchise and licence agreements with brands such as IKEA, INTERSPORT and Foot Locker, combining their global brand strength with the group's deep local market expertise. The partnerships provide exposure to product categories with favourable growth profiles, including home furnishings,
Services bancaires / financiers, Matériel informatique, Logiciels, Santé
2026-07-30 10:29 AM EDT | Edison Group
Therma Bright Inc. Completes Debt Settlements
Toronto, Ontario--(Newsfile Corp. - July 30, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced medical device technologies, announces that further to its press release of June 23, 2026, it has now issued an aggregate of 6,613,999 common shares at a deemed price of $0.06 per share to settle aggregate debt of $396,840. All shares issued in relation to these debt settlements a
Technologies, Biotechnologies, Santé
2026-07-30 8:16 AM EDT | Therma Bright Inc.
Delota Reports Financial Results for the Year Ended March 31, 2026
Highlights: Total revenue of $34.8 million for the Year Ended 2026 Total System-Wide Revenue of $39.8 million for the Year Ended 2026 33% gross profit margin for the Year Ended 2026 Segmented revenue for the Year Ended 2026: Vape - B2C: $19.8 million, B2B: $11.1 million Cannabis - B2C: $3.9 million Launched 180 Smoke V
Commerce de détail, Cannabis, Santé, Dispensaires de cannabis
2026-07-30 7:30 AM EDT | Delota Corp.
TempraMed Uplists to OTCQB Venture Market and Achieves DTC Eligibility, Expanding Access to U.S. Investors
Toronto, Ontario--(Newsfile Corp. - July 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company") is pleased to announce that its common shares have been approved to commence trading on the OTCQB Venture Market, operated by OTC Markets Group Inc. The Company's shares are also now DTC eligible, significantly enhancing the accessibility and efficiency of trading for U.S. investors. Tempra
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-07-30 7:00 AM EDT | TempraMed Technologies Ltd.
Psyched Wellness Launches Strategic Review to Unlock Shareholder Value
Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) ("Psyched Wellness" or the "Company"), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, announces that its Board of Directors has commenced a strategic review process designed to evaluate opportunities to enhance and accelerate value creation for shareholders ("Strategic Review").
Cannabis, Santé, Psychédéliques, Producteurs de cannabis
2026-07-29 5:42 PM EDT | Psyched Wellness Ltd.
Tersis Technologies Appoints Plastics Recycling Veteran Paul Vanderpool as Strategic Advisor to PolyCycle
Brooksville, Florida--(Newsfile Corp. - July 29, 2026) - Tersis Technologies, Inc. (OTCID: TERS) ("Tersis" or the "Company"), a clean technology company focused on transforming waste streams into valuable resources, today announced the appointment of plastics recycling veteran Paul Vanderpool as Strategic Advisor to PolyCycle™, the Company's plastics recycling and remanufacturing division.
Agriculture, Énergie, Énergies de substitution, Santé
2026-07-29 11:16 AM EDT | Tersis Technologies Inc.
Visionary Holdings' Subsidiary Nanjing Tuoyuanjian Health Technology Co., Ltd. Enters into Distribution Agreement with Suncare (Shanghai) Health Technology Co., Ltd.
Nanjing, China--(Newsfile Corp. - July 29, 2026) - Visionary Holdings Inc. (NASDAQ: GV) ("Visionary" or the "Company") today announced that its subsidiary, Nanjing Tuoyuanjian Health Technology Co., Ltd. ("GV Nanjing"), has entered into a Distribution Agreement with Suncare (Shanghai) Health Technology Co., Ltd. ("Suncare"), an AI-driven digital health and community-based senior care platform in China. Under the Distribution Agreement, GV Nanjing will supply stem cell aesthetic products
2026-07-29 9:30 AM EDT | Visionary Holdings Inc.
BioHarvest Sciences to Present at the Canaccord Genuity 46th Annual Growth Conference
British Columbia and Rehovot, Israel--(Newsfile Corp. - July 29, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will present at the upcoming Canaccord Genuity 46th Annual Growth Conference, to be held on August 11-13, 2026, in Boston, Massachusetts. In ad
Biotechnologies, Pharmaceutique, Santé
2026-07-29 8:00 AM EDT | BioHarvest Sciences Inc.
Red Light Holland Reports Fiscal 2026 Audited Year-End Results and Provides Update on Rhelion Life Sciences
Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to report its audited annual consolidated financial statements and management's discussion and analysis ("MD&A") for the fiscal years ended March 31, 2026 and 2025. All figures are reported in Canadian dol
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-07-29 7:53 AM EDT | Rhelion Life Sciences Corp.
Adia Med Completes Phase 1 and Formally Launches Phase 2 of Autism Spectrum Disorder Clinical Study
Winter Park, Florida--(Newsfile Corp. - July 29, 2026) - Adia Med Inc. (OTCQB: ADIA) today announced two distinct milestones in its Autism Spectrum Disorder (ASD) clinical research study (ClinicalTrials.gov Identifier: NCT07304440): the completion of Phase 1 treatment for the study's first cohort of children, and the formal launch of Phase 2 of the study. Separately, the company confirmed that a new cohort of 30 children will begin its own Phase 1 treatment on October 1, 2026, as part of the
Soins de santé et hôpitaux, Santé
2026-07-29 6:00 AM EDT | Adia Med Inc.
Restart Life Sciences Announces Strategic Focus on Targeted M&A Expansion in Health and CPG Sectors
Vancouver, British Columbia--(Newsfile Corp. - July 29, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide a corporate update on its strategic growth initiatives as the Company actively pursues targeted merger and acquisition opportunities to further expand its presence in the health and wellness segments of the consumer packaged goods sector. Following the acquisition and successful operational rollout o
Technologies, Biotechnologies, Santé
2026-07-29 6:00 AM EDT | Restart Life Sciences Corp.
Rapid Dose Therapeutics (DOSE) (RDTCF) and Bodhi Health Expand Distribution and Sales of CurcuWIN(R) QuickStrip(TM) Curcumin Across Canada
Burlington, Ontario--(Newsfile Corp. - July 28, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("Rapid Dose" or "RDT"), a Canadian biotechnology company, and Ontario-based Bodhi Health Inc. ("Bodhi Health") today announced an expansion of their coordinated distribution, sales and market-development efforts for Bodhi Health Sublingual Curcumin, manufactured using Rapid Dose's proprietary QuickStrip™ oral thin-film technology and the patented CurcuWIN® curcumin form
2026-07-28 4:05 PM EDT | Rapid Dose Therapeutics Corp.